Abstract
Parasitic diseases affect more than 2 billion people globally and cause substantial morbidity and mortality, particularly among the world's poorest people. This overview focuses on the treatment of the major protozoan and helminth infections in humans. Recent developments in antiparasitic therapy include the expansion of artemisinin-based therapies for malaria, new drugs for soil-transmitted helminths and intestinal protozoa, expansion of the indications for antiparasitic drug treatment in patients with Chagas disease, and the use of combination therapy for leishmaniasis and human African trypanosomiasis.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Amebiasis / drug therapy
-
Anthelmintics / therapeutic use*
-
Antiparasitic Agents / therapeutic use
-
Antiprotozoal Agents / therapeutic use*
-
Cestode Infections / drug therapy
-
Chagas Disease / drug therapy
-
Drug Resistance
-
Giardiasis / drug therapy
-
Helminthiasis / drug therapy*
-
Humans
-
Leishmaniasis / drug therapy
-
Malaria / drug therapy
-
Nematode Infections / drug therapy
-
Parasitic Diseases / drug therapy
-
Protozoan Infections / drug therapy*
-
Toxoplasmosis / drug therapy
-
Trematode Infections / drug therapy
-
Trypanosomiasis, African / drug therapy
Substances
-
Anthelmintics
-
Antiparasitic Agents
-
Antiprotozoal Agents